A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
详细信息 查看全文
- 作者：Sheena Kayaniyil ; Greta Lozano-Ortega ; Heather A. Bennett…
- 关键词：Exenatide once weekly ; GLP ; 1 receptor agonist ; Network meta ; analysis ; Type 2 diabetes
- 刊名：Diabetes Therapy
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：7
- 期：1
- 页码：27-43
- 全文大小：524 KB
- 刊物主题：Internal Medicine; Diabetes; Cardiology; Endocrinology;
- 出版者：Springer Healthcare
- ISSN：1869-6961
文摘
Introduction Exenatide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA), approved for treatment of type 2 diabetes mellitus (T2DM). There is limited direct evidence comparing the efficacy and tolerability of exenatide 2 mg once weekly (QW) to other GLP-1 RAs. A network meta-analysis (NMA) was conducted to estimate the relative efficacy and tolerability of exenatide QW versus other GLP-1 RAs for the treatment of adults with T2DM inadequately controlled on metformin monotherapy.